|
|
Volumn 297, Issue 6, 2007, Pages 573-574
|
|
FDA panel seeks to balance risks in warnings for antidepressants
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
ANTIDEPRESSANT AGENT;
CITALOPRAM;
DULOXETINE;
ESCITALOPRAM;
FLUOXETINE;
FLUVOXAMINE;
MIRTAZAPINE;
NEFAZODONE;
PAROXETINE;
PLACEBO;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
VENLAFAXINE;
ADOLESCENCE;
ADULTHOOD;
BIPOLAR DISORDER;
CLINICAL TRIAL;
DEATH;
DEPRESSION;
DIAGNOSTIC ERROR;
DRUG INFORMATION;
DRUG LABELING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
GROUPS BY AGE;
HUMAN;
HYPOMANIA;
MANIA;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
RISK REDUCTION;
SHORT SURVEY;
SUICIDAL BEHAVIOR;
SUICIDAL IDEATION;
SUICIDE;
|
|
EID: 33846989778
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.297.6.573 Document Type: Short Survey |
|
Times cited : (11)
|
|
References (0)
|